Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 1
1958 1
1959 1
1960 1
1961 6
1962 1
1965 2
1967 2
1969 2
1970 3
1971 7
1972 3
1973 5
1974 3
1975 2
1977 4
1978 5
1979 2
1980 6
1981 10
1982 10
1983 11
1984 14
1985 17
1986 19
1987 29
1988 29
1989 24
1990 35
1991 19
1992 27
1993 30
1994 31
1995 37
1996 41
1997 48
1998 43
1999 56
2000 56
2001 64
2002 50
2003 52
2004 66
2005 47
2006 69
2007 75
2008 66
2009 68
2010 87
2011 96
2012 99
2013 99
2014 78
2015 114
2016 105
2017 102
2018 93
2019 78
2020 92
2021 60
Text availability
Article attribute
Article type
Publication date

Search Results

2,119 results
Results by year
Filters applied: . Clear all
Page 1
Diabetes and cancer risk: A Mendelian randomization study.
Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, Shimazu T, Inoue M, Noda M, Tsugane S, Iwasaki M. Goto A, et al. Among authors: noda m. Int J Cancer. 2020 Feb 1;146(3):712-719. doi: 10.1002/ijc.32310. Epub 2019 Apr 25. Int J Cancer. 2020. PMID: 30927373 Free PMC article.
Metabolic Plasticity of Astrocytes and Aging of the Brain.
Morita M, Ikeshima-Kataoka H, Kreft M, Vardjan N, Zorec R, Noda M. Morita M, et al. Among authors: noda m. Int J Mol Sci. 2019 Feb 21;20(4):941. doi: 10.3390/ijms20040941. Int J Mol Sci. 2019. PMID: 30795555 Free PMC article. Review.
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Among authors: noda m. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition.
Das NA, Carpenter AJ, Belenchia A, Aroor AR, Noda M, Siebenlist U, Chandrasekar B, DeMarco VG. Das NA, et al. Among authors: noda m. Cell Signal. 2020 Apr;68:109506. doi: 10.1016/j.cellsig.2019.109506. Epub 2019 Dec 17. Cell Signal. 2020. PMID: 31862399 Free PMC article.
2,119 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page